Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, open label, non-randomized study in subjects with histologically
confirmed diagnosis of advanced KRAS wild type adenocarcinoma of the colon or rectum, who
have not received prior chemotherapy for metastatic disease.
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health
Collaborators:
Bristol-Myers Squibb Eli Lilly and Company ImClone LLC